421 related articles for article (PubMed ID: 22595146)
21. Nanoparticle and targeted systems for cancer therapy.
Brannon-Peppas L; Blanchette JO
Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294
[TBL] [Abstract][Full Text] [Related]
22. [Targeting of anti-cancer drugs with nano-sized carrier system].
Yokoyama M; Okano T
Nihon Rinsho; 1998 Dec; 56(12):3227-34. PubMed ID: 9883646
[TBL] [Abstract][Full Text] [Related]
23. [Significance of arterial infusion of SMANCS-dissolved Lipiodol in therapeutic strategies for hepatocellular carcinoma].
Jin-no K
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():90-8. PubMed ID: 9512695
[TBL] [Abstract][Full Text] [Related]
24. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
25. [Principle and therapeutic effect of lipophilic anticancer agent [SMANCS/lipiodol]: selective targeting with oily contrast medium].
Maeda H
Gan To Kagaku Ryoho; 1989 Oct; 16(10):3323-31. PubMed ID: 2552930
[TBL] [Abstract][Full Text] [Related]
26. Polymer-protein and polymer-drug conjugates in cancer therapy.
Thanou M; Duncan R
Curr Opin Investig Drugs; 2003 Jun; 4(6):701-9. PubMed ID: 12901229
[TBL] [Abstract][Full Text] [Related]
27. The influence of conjugates on their functionality in the therapy of solid tumors.
Osadnik KM; Jelonek K
Acta Pol Pharm; 2013; 70(3):379-86. PubMed ID: 23757927
[TBL] [Abstract][Full Text] [Related]
28. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
29. The dawning era of polymer therapeutics.
Duncan R
Nat Rev Drug Discov; 2003 May; 2(5):347-60. PubMed ID: 12750738
[TBL] [Abstract][Full Text] [Related]
30. Exploiting EPR in polymer drug conjugate delivery for tumor targeting.
Modi S; Prakash Jain J; Domb AJ; Kumar N
Curr Pharm Des; 2006; 12(36):4785-96. PubMed ID: 17168778
[TBL] [Abstract][Full Text] [Related]
31. Tumor targeting via EPR: Strategies to enhance patient responses.
Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
[TBL] [Abstract][Full Text] [Related]
32. Passive tumor targeting of soluble macromolecules and drug conjugates.
Seymour LW
Crit Rev Ther Drug Carrier Syst; 1992; 9(2):135-87. PubMed ID: 1386002
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
Greco F; Vicent MJ
Adv Drug Deliv Rev; 2009 Nov; 61(13):1203-13. PubMed ID: 19699247
[TBL] [Abstract][Full Text] [Related]
34. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.
Maruyama K
Adv Drug Deliv Rev; 2011 Mar; 63(3):161-9. PubMed ID: 20869415
[TBL] [Abstract][Full Text] [Related]
35. [Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome].
Maeda H; Konno T
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):773-82. PubMed ID: 2985005
[TBL] [Abstract][Full Text] [Related]
36. Polymer conjugates: nanosized medicines for treating cancer.
Vicent MJ; Duncan R
Trends Biotechnol; 2006 Jan; 24(1):39-47. PubMed ID: 16307811
[TBL] [Abstract][Full Text] [Related]
37. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors.
Nagamitsu A; Greish K; Maeda H
Jpn J Clin Oncol; 2009 Nov; 39(11):756-66. PubMed ID: 19596662
[TBL] [Abstract][Full Text] [Related]
38. Advocation and advancements of EPR effect theory in drug delivery science: A commentary.
Hashida M
J Control Release; 2022 Jun; 346():355-357. PubMed ID: 35483640
[TBL] [Abstract][Full Text] [Related]
39. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
Danhier F; Feron O; Préat V
J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
[TBL] [Abstract][Full Text] [Related]
40. [Targeting cancer chemotherapy using lipiodol as a carrier of anticancer drugs for hepatocellular carcinoma].
Konno T; Maeda H
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):1043-50. PubMed ID: 2839112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
